Release Date: 21-Jul-2024
Selinexor, developed by Karyopharm Therapeutics, is a groundbreaking oral Selective Inhibitor of Nuclear Export (SINE) compound. It works by inhibiting the nuclear export protein exportin 1 (XPO1). In July 2019, the FDA approved Selinexor, marketed as Xpovio, for treating adult patients with relapsed/refractory multiple myeloma (R/R MM) and diffuse large B-cell lymphoma (R/R DLBCL) in combination with dexamethasone.
Expanding its global reach, Karyopharm’s partner Antengene Corporation received conditional approval from China’s National Medical Products Administration (NMPA) in December 2021 for Xpovio in R/R MM. By December 2023, Xpovio was added to China’s National Reimbursement Drug List for this indication. In July 2024, the NMPA further approved Xpovio for R/R DLBCL, marking significant milestones in Selinexor’s journey to provide innovative treatment options for patients with these challenging hematologic malignancies.
For More Information on Drug Trials in China Contact